Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report)’s stock price was up 1.8% during mid-day trading on Friday . The company traded as high as $1.67 and last traded at $1.66. Approximately 96,748 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 556,411 shares. The stock had previously closed at $1.63.
Alzamend Neuro Stock Performance
The company has a market capitalization of $13.25 million, a price-to-earnings ratio of -1.68 and a beta of -0.03. The business has a 50 day moving average price of $2.39 and a 200-day moving average price of $4.88.
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last announced its quarterly earnings data on Wednesday, September 11th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.38) by $1.13.
Institutional Inflows and Outflows
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
See Also
- Five stocks we like better than Alzamend Neuro
- How to Calculate Return on Investment (ROI)
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- What is a Stock Market Index and How Do You Use Them?
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- Election Stocks: How Elections Affect the Stock Market
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.